Strides receives USFDA nod to manufacture constipation drug at its Bangalore plant


New Delhi: Strides Shasun Thursday said it has received an approval from the US health regulator for Polyethylene Elycol 3350 used for treating constipation.

PharmaThinkstock

In a BSE filing, Strides Shasun said: "It has received approval from the US Food and Drug Administration (USFDA) for Polyethylene Glycol 3350, powder for solution 17 grams/capful and 17 grams/packet (OTC)".

The company said it will manufacture the product at its Bangalore plant and launch the product in the fourth quarter of this fiscal.


Quoting IMS sales data, Strides Shasun said the US market for Polyethylene Glycol 3350, powder for solution is around $260 million.

Strides Shasun's shares were trading 0.88 percent higher at Rs 973.50 apiece on BSE.


Published Date: Aug 25, 2016 12:58 pm | Updated Date: Aug 25, 2016 12:58 pm



Also See